-+ 0.00%
-+ 0.00%
-+ 0.00%

10x Genomics To Incorporate Lunit's AI-Powered Pathology Platform Into Its Oncology Biomarker Discovery Workflow

Benzinga·09/10/2026 13:04:26
语音播报

Lunit (KRX: 328130), a leading provider of AI for cancer diagnostics and precision oncology, today announced that 10x Genomics, Inc. (Nasdaq: TXG) will incorporate Lunit's AI-powered pathology platform, Lunit SCOPE IO, into its oncology biomarker discovery workflow. Lunit SCOPE IO will be used to analyze Hematoxylin and Eosin (H&E) pathology images alongside spatial molecular data generated from 10x's oncology-focused clinical research studies.